symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
NVIV,1.05,0.846871,14517,3260723,0,0.81-3.06,0.03,InVivo Therapeutics Holdings Corp.,USD,0001292519,US46186M6057,46186M605,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.invivotherapeutics.com,"InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",Dr. Richard M. Toselli,Healthcare,US,6,617 863 5500,One Kendall Square,Cambridge,MA,02139,14.2578,16.4578,https://financialmodelingprep.com/image-stock/NVIV.png,2010-11-15,False,False,True,False,False
